

Valeant Pharmaceuticals International, Inc.  
Form 8-K  
November 18, 2013

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**  
**Washington, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934**

**Date of Report (Date of the earliest event reported): November 15, 2013 (November 15, 2013)**

**Valeant Pharmaceuticals International, Inc.**

**(Exact name of registrant as specified in its charter)**

**British Columbia, Canada**  
**(State or other jurisdiction**  
  
**of incorporation)**

**001-14956**  
**(Commission**  
  
**File Number)**  
**2150 St. Elzéar Blvd. West,**  
  
**Laval, Quebec**

**98-0448205**  
**(IRS Employer**  
  
**Identification No.**

**Canada H7L 4A8**

**(Address of principal executive offices)(Zip Code)**

**514-744-6792**

**(Registrant's telephone number, including area code)**

**(Former name or former address, if changed since last report)**

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- .. Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- .. Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- .. Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- .. Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

**Item 8.01 Other Events.**  
**Pricing of Notes Offering**

On November 15, 2013, Valeant Pharmaceuticals International, Inc. (the Company ) issued a press release announcing that it has priced its offering of 5.625% senior unsecured notes due 2021. The Company increased the offering to \$900 million from \$850 million aggregate principal amount of such notes.

A copy of the press release is attached hereto as Exhibit 99.1 and incorporated herein by reference.

**Item 9.01 Financial Statements and Exhibits.**

(d) Exhibits

<b>Exhibit Number</b>	<b>Description</b>
99.1	Press Release announcing the pricing of the offering, dated November 15, 2013

**Signatures**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

VALEANT PHARMACEUTICALS  
INTERNATIONAL, INC.

By: /s/ Howard B. Schiller  
Name: Howard B. Schiller  
Title: Executive Vice President and Chief  
Financial Officer

Date: November 15, 2013

**EXHIBIT INDEX**

<b>Exhibit Number</b>	<b>Description</b>
99.1	Press Release announcing the pricing of the offering, dated November 15, 2013